{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T16:15:40Z","timestamp":1790957740410,"version":"4.1.0"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2006,9,1]],"date-time":"2006-09-01T00:00:00Z","timestamp":1157068800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Curr Rheumatol Rep"],"published-print":{"date-parts":[[2006,9]]},"DOI":"10.1007\/s11926-006-0064-9","type":"journal-article","created":{"date-parts":[[2007,6,2]],"date-time":"2007-06-02T16:26:21Z","timestamp":1180801581000},"page":"348-354","source":"Crossref","is-referenced-by-count":36,"title":["Management of psoriatic arthritis: The therapeutic interface between rheumatology and dermatology"],"prefix":"10.1007","volume":"8","author":[{"given":"Philip","family":"Mease","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"64_CR1","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1002\/1529-0131(200104)45:2<151::AID-ANR168>3.0.CO;2-T","volume":"45","author":"JA Husted","year":"2001","unstructured":"Husted JA, Gladman DD, Farewell VT, Cook RJ: Healthrelated quality of life of patients with psoriatic arthritis: a comparison with patients with rheumatoid arthritis. Arthritis Rheum 2001, 45:151\u2013158.","journal-title":"Arthritis Rheum"},{"key":"64_CR2","doi-asserted-by":"crossref","first-page":"1868","DOI":"10.1002\/art.1780401021","volume":"40","author":"K Wong","year":"1997","unstructured":"Wong K, Gladman DD, Husted J, et al.: Mortality studies in psoriatic arthritis: results from a single outpatient clinic. Causes and risk of death. Arthritis Rheum 1997, 40:1868\u20131872.","journal-title":"Arthritis Rheum"},{"key":"64_CR3","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/0049-0172(73)90035-8","volume":"3","author":"J Moll","year":"1973","unstructured":"Moll J, Wright V: Psoriatic arthritis. Semin Arthritis Rheum 1973, 3:55\u201378.","journal-title":"Semin Arthritis Rheum"},{"issue":"Suppl_2","key":"64_CR4","doi-asserted-by":"crossref","first-page":"ii3","DOI":"10.1136\/ard.2004.032318","volume":"64","author":"P Helliwell","year":"2005","unstructured":"Helliwell P, Taylor W: Classification and diagnostic criteria for psoriatic arthritis. Ann Rheum Dis 2005, 64(Suppl_2):ii3-ii8.","journal-title":"Ann Rheum Dis"},{"key":"64_CR5","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.semarthrit.2004.05.001","volume":"34","author":"W Taylor","year":"2004","unstructured":"Taylor W, Marchesoni A, Arreghini M, et al.: A comparison of the performance characteristics of classification criteria for the diagnosis of psoriatic arthritis. Semin Arthritis Rheum 2004, 34:575\u2013584.","journal-title":"Semin Arthritis Rheum"},{"key":"64_CR6","doi-asserted-by":"crossref","first-page":"2665","DOI":"10.1002\/art.21972","volume":"54","author":"W Taylor","year":"2006","unstructured":"Taylor W: ClASsification criteria for Psoriatic ARthritis: development of new criteria from a large international study. Arthritis Rheum 2006, 54:2665\u20132673. Key paper describing the results of the CASPAR study, which establishes an updated classification criteria for PsA.","journal-title":"Arthritis Rheum"},{"key":"64_CR7","first-page":"511","volume":"53","author":"DG Leonard","year":"1978","unstructured":"Leonard DG, O\u2019Duffy JD, Rogers RS: Prospective analysis of psoriatic arthritis in patients hospitalized for psoriasis. Mayo Clin Proc 1978, 53:511\u2013518.","journal-title":"Mayo Clin Proc"},{"key":"64_CR8","first-page":"1247","volume":"27","author":"M Shbeeb","year":"2000","unstructured":"Shbeeb M, Uramoto KM, Gibson LE, et al.: The epidemiology of psoriatic arthritis in Olmsted County, Minnesota, USA, 1982\u20131991. J Rheumatol 2000, 27:1247\u20131250.","journal-title":"J Rheumatol"},{"key":"64_CR9","unstructured":"Salonen S: The EUROPSO psoriasis patient study: treatment history and satisfaction reported by 17,900 members of European psoriasis patients associations. Poster presented at the Spring Symposium of the European Academy of Dermatology and Venereology. Malta; February 2003."},{"key":"64_CR10","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1016\/j.jaad.2005.03.046","volume":"53","author":"JM Gelfand","year":"2005","unstructured":"Gelfand JM, Gladman DD, Mease PJ, et al.: Epidemiology of psoriatic arthritis in the population of the United States. J Am Acad Dermatol 2005, 53:573.","journal-title":"J Am Acad Dermatol"},{"key":"64_CR11","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1080\/000155598442809","volume":"78","author":"A Offidani","year":"1998","unstructured":"Offidani A, Cellini A, Valeri G, Giovagnoni A: Subclinical joint involvement in psoriasis: magnetic resonance imaging and X-ray.ndings. Acta Derm Venereol 1998, 78:463\u2013465.","journal-title":"Acta Derm Venereol"},{"key":"64_CR12","doi-asserted-by":"crossref","first-page":"R359","DOI":"10.1186\/ar1501","volume":"7","author":"D Baeten","year":"2005","unstructured":"Baeten D, Kruithof E, De Rycke L, et al.: Infiltration of the synovial membrane with macrophage subsets and polymorphonuclear cells reflects global disease activity in spondyloarthropathy. Arthritis Res Ther 2005, 7:R359-R369.","journal-title":"Arthritis Res Ther"},{"key":"64_CR13","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1002\/art.21155","volume":"52","author":"L Rycke De","year":"2005","unstructured":"De RyckeL, Vandooren B, Kruithof E, et al.: Tumor necrosis factor alpha blockade treatment down-modulates the increased systemic and local expression of Toll-like receptor 2 and Toll-like receptor 4 in spondylarthropathy. Arthritis Rheum 2005, 52:2146\u20132158.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"64_CR14","doi-asserted-by":"crossref","first-page":"ii26","DOI":"10.1136\/ard.2004.031740","volume":"65","author":"D Veale","year":"2005","unstructured":"Veale D, Ritchlin C, FitzGerald O: Immunopathology of psoriasis and psoriatic arthritis. Ann Rheum Dis 2005, 65(Suppl 2):ii26-ii29.","journal-title":"Ann Rheum Dis"},{"key":"64_CR15","doi-asserted-by":"crossref","first-page":"R569","DOI":"10.1186\/ar1698","volume":"7","author":"E Kruithof","year":"2005","unstructured":"Kruithof E, Baeten D, De Rycke L, et al.: Synovial histopathology of psoriatic arthritis, both oligo- and polyarticular, resembles spondyloarthropathy more than it does rheumatoid arthritis. Arthritis Res Ther 2005, 7:R569-R580. Establishes the close relationship of the subsets of the spondyloarthropathies, especially AS and PsA, at a synovial cellular and immunohistochemical level, and their distinction from RA.","journal-title":"Arthritis Res Ther"},{"issue":"Suppl 2","key":"64_CR16","doi-asserted-by":"crossref","first-page":"ii30","DOI":"10.1136\/ard.2004.031120","volume":"64","author":"J Krueger","year":"2005","unstructured":"Krueger J, Bowcock A Psoriasis pathophysiology: current concepts of pathogenesis. Ann Rheum Dis 2005, 64(Suppl 2):ii30-ii36. Comprehensive review of psoriasis pathophysiology.","journal-title":"Ann Rheum Dis"},{"key":"64_CR17","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jaad.2004.06.013","volume":"52","author":"P Mease","year":"2005","unstructured":"Mease P, Goffe BS: Diagnosis and treatment of psoriatic arthritis. J Am Acad Dermatol 2005, 52:1\u201319. Comprehensive review of PsA: diagnosis, pathophysiology, assessment, and management.","journal-title":"J Am Acad Dermatol"},{"key":"64_CR18","doi-asserted-by":"crossref","unstructured":"Fransen J, Antoni C, Mease P, et al.: Performance of response criteria for assessing peripheral arthritis in patients with psoriatic arthritis: analysis of data from randomized, controlled trials of two TNF inhibitors. Ann Rheum Dis 2006, In press.","DOI":"10.1136\/ard.2006.051706"},{"key":"64_CR19","first-page":"2146","volume":"25","author":"JA Husted","year":"1998","unstructured":"Husted JA, Gladman DD, Cook RJ, Farewell VT: Responsiveness of health status instruments to changes in articular status and perceived health in patients with psoriatic arthritis. J Rheumatol 1998, 25:2146\u20132155.","journal-title":"J Rheumatol"},{"key":"64_CR20","first-page":"511","volume":"24","author":"JA Husted","year":"1997","unstructured":"Husted JA, Gladman DD, Farewell VT, et al.: Validating the SF-36 health survey questionnaire in patients with psoriatic arthritis. J Rheumatol 1997, 24:511\u2013517.","journal-title":"J Rheumatol"},{"issue":"Suppl 9","key":"64_CR21","first-page":"S402","volume":"52","author":"A Singh","year":"2005","unstructured":"Singh A, Mease P, Yu E, et al.: Health Assessment Questionnaire has similar psychometric properties in psoriatic arthritis and rheumatoid arthritis. Arthritis Rheum 2005, 52(Suppl 9):S402.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"64_CR22","doi-asserted-by":"crossref","first-page":"ii49","DOI":"10.1136\/ard.2004.034165","volume":"64","author":"P Mease","year":"2005","unstructured":"Mease P, Antoni C, Gladman DD, Taylor W: Psoriatic arthritis assessment tools in clinical trials. Ann Rheum Dis 2005, 64(Suppl 2):ii49-ii54.","journal-title":"Ann Rheum Dis"},{"key":"64_CR23","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1002\/art.11417","volume":"50","author":"DD Gladman","year":"2004","unstructured":"Gladman DD, Helliwell P, Mease PJ, et al.: Assessment of patients with psoriatic arthritis: a review of currently available measures. Arthritis Rheum 2004, 50:24\u201335.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 2","key":"64_CR24","doi-asserted-by":"crossref","first-page":"ii61","DOI":"10.1136\/ard.2004.030809","volume":"64","author":"D Heijde van der","year":"2005","unstructured":"van der HeijdeD, Sharp J, Wassenberg S, et al.: Psoriatic arthritis imaging: a review of scoring methods. Ann Rheum Dis 2005, 64(Suppl 2):ii61-ii64.","journal-title":"Ann Rheum Dis"},{"key":"64_CR25","first-page":"38","volume":"4","author":"P Mease","year":"2006","unstructured":"Mease P, van der Heidje D: Joint damage in psoriatic arthritis: how is it assessed and can it be prevented? Int J Adv Rheumatol 2006, 4:38\u201348.","journal-title":"Int J Adv Rheumatol"},{"issue":"Suppl 2","key":"64_CR26","doi-asserted-by":"crossref","first-page":"ii55","DOI":"10.1136\/ard.2004.033928","volume":"64","author":"P Ory","year":"2005","unstructured":"Ory P, Gladman DD, Mease P: Psoriatic arthritis and imaging. Ann Rheum Dis 2005, 64(Suppl 2):ii55-ii57.","journal-title":"Ann Rheum Dis"},{"key":"64_CR27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jbspin.2005.09.003","volume":"73","author":"X Baraliakos","year":"2006","unstructured":"Baraliakos X, Braun J: Magnetic resonance imaging in spondyloarthropathies. Joint Bone Spine 2006, 73:1\u20133.","journal-title":"Joint Bone Spine"},{"key":"64_CR28","first-page":"2262","volume":"32","author":"D Gladman","year":"2005","unstructured":"Gladman D, Mease P, Krueger G, et al.: Outcome measures in psoriatic arthritis. J Rheumatol 2005, 32:2262\u20132269. Summary of OMERACT 7 workshop on PsA domains and outcome measures.","journal-title":"J Rheumatol"},{"issue":"Suppl 64","key":"64_CR29","doi-asserted-by":"crossref","first-page":"ii83","DOI":"10.1136\/ard.2004.030791","volume":"64","author":"M Lebwohl","year":"2005","unstructured":"Lebwohl M, Ting P, Koo J: Psoriasis treatment: traditional therapy. Ann Rheum Dis 2005, 64(Suppl 64):ii83-ii86.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"64_CR30","doi-asserted-by":"crossref","first-page":"ii78","DOI":"10.1136\/ard.2004.034157","volume":"64","author":"P Mease","year":"2005","unstructured":"Mease P, Antoni C: Psoriatic arthritis treatment: biological response modifiers. Ann Rheum Dis 2005, 64(Suppl 2):ii78-ii82. Current review of biologics in PsA.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 2","key":"64_CR31","doi-asserted-by":"crossref","first-page":"ii74","DOI":"10.1136\/ard.2004.030783","volume":"64","author":"P Nash","year":"2005","unstructured":"Nash P, Clegg DO: Psoriatic arthritis therapy: NSAIDs and traditional DMARDs. Ann Rheum Dis 2005, 64(Suppl 2):ii74-ii77.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 64","key":"64_CR32","doi-asserted-by":"crossref","first-page":"ii87","DOI":"10.1136\/ard.2004.032276","volume":"64","author":"L Winterfield","year":"2005","unstructured":"Winterfield L, Menter A, Gordon KB, Gottieb A: Psoriasis treatment: current and emerging directed therapies. Ann Rheum Dis 2005, 64(Suppl 64):ii87-ii90.","journal-title":"Ann Rheum Dis"},{"key":"64_CR33","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/3-540-27190-2_20","volume-title":"Psoriasis and Psoriatic Arthritis","author":"KB Gordon","year":"2005","unstructured":"Gordon KB, Ruderman EM: Synthesis and conclusion. In Psoriasis and Psoriatic Arthritis. Edited by Gordon KB, Ruderman EM. Berlin, Germany: Springer-Verlag Berlin Heidelberg; 2005:245\u2013250."},{"key":"64_CR34","doi-asserted-by":"crossref","first-page":"1939","DOI":"10.1002\/art.20253","volume":"50","author":"JP Kaltwasser","year":"2004","unstructured":"Kaltwasser JP, Nash P, Gladman D, et al.: Efficacy and safety of leflunomide in the treatment of psoriatic arthritis and psoriasis. Arthritis Rheum 2004, 50:1939\u20131950.","journal-title":"Arthritis Rheum"},{"key":"64_CR35","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1136\/ard.2004.024463","volume":"64","author":"AD Fraser","year":"2005","unstructured":"Fraser AD, van Kuijk AW, Westhovens R, et al.: A randomized, double blind, placebo controlled, multicentre trial of combination therapy with methotrexate plus cyclosporin in patients with active psoriatic arthritis. Ann Rheum Dis 2005, 64:859\u2013864.","journal-title":"Ann Rheum Dis"},{"key":"64_CR36","unstructured":"Enbrel (etanercept) prescribing information. Thousand Oaks, CA: Immunex Corporation; 2003."},{"key":"64_CR37","unstructured":"Remicade (infliximab) prescribing information. Malvern, PA: Centocor Inc.; 2003."},{"key":"64_CR38","unstructured":"HumiraTM (adalimumab) prescribing information. North Chicago, IL: Abbott Laboratories; 2003."},{"key":"64_CR39","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1002\/art.20335","volume":"50","author":"P Mease","year":"2004","unstructured":"Mease P, Kivitz A, Burch F, et al.: Etanercept treatment of psoriatic arthritis: safety, efficacy, and effect on disease progression. Arthritis Rheum 2004, 50:2264\u20132272. 0Pivotal phase 3 study of etanercept in PsA.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"64_CR40","first-page":"391","volume":"63","author":"P Mease","year":"2004","unstructured":"Mease P, Ganguly L, Wanke E, et al.: How much improvement in functional status is considered important by patients with active psoriatic arthritis: applying the outcome measures in rheumatoid arthritis clinical trials (OMERACT) group guidelines. Ann Rheum Dis 2004, 63(Suppl 1):391.","journal-title":"Ann Rheum Dis"},{"key":"64_CR41","first-page":"712","volume":"33","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Kivitz AJ, Burch FX, et al.: Continued inhibition of radiographic progression in patients with psoriatic arthritis following 2 years of treatment with etanercept. J Rheumatol 2006, 33:712\u2013721.","journal-title":"J Rheumatol"},{"key":"64_CR42","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1136\/ard.2004.032268","volume":"64","author":"C Antoni","year":"2005","unstructured":"Antoni C, Krueger GG, de VlamK, et al.: Infliximab improves signs and symptoms of psoriatic arthritis: results of the IMPACT 2 trial. Ann Rheum Dis 2005, 64:1150\u20131157. Pivotal phase 3 study of infliximab in PsA.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"64_CR43","first-page":"S281","volume":"52","author":"D Heidje Van der","year":"2005","unstructured":"Van der HeidjeD, Gladman D, Kavanaugh A, et al.: Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis: 54 week results from IMPACT 2. Arthritis Rheum 2005, 52(Suppl 9):S281.","journal-title":"Arthritis Rheum"},{"issue":"Suppl 9","key":"64_CR44","first-page":"S616","volume":"50","author":"P Mease","year":"2004","unstructured":"Mease P, Kavanaugh A, Krueger G, et al.: Infliximab improves psoriasis regardless of arthritis response in patients with active psoriatic arthritis: results from IMPACT 2 Trial. Arthritis Rheum 2004, 50(Suppl 9):S616.","journal-title":"Arthritis Rheum"},{"key":"64_CR45","doi-asserted-by":"crossref","first-page":"3279","DOI":"10.1002\/art.21306","volume":"58","author":"P Mease","year":"2005","unstructured":"Mease P, Gladman D, Ritchlin C: Adalimumab in the treatment of patients with moderately to severely active psoriatic arthritis: Results of ADEPT. Arthritis Rheum 2005, 58:3279\u20133289. Pivotal phase 3 study of adalimumab in PsA.","journal-title":"Arthritis Rheum"},{"key":"64_CR46","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1136\/ard.2005.041129","volume":"65","author":"J Zochling","year":"2006","unstructured":"Zochling J, van der Heijde D, Dougados M, Braun J: Current evidence for the management of ankylosing spondylitis a systematic literature review for the ASAS\/EULAR management recommendations in ankylosing spondylitis. Ann Rheum Dis 2006, 65:423\u2013432. Key summary review paper of therapies for AS.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"64_CR47","first-page":"36","volume":"64","author":"CA Marra","year":"2005","unstructured":"Marra CA: Valuing health states and preferences of patients. Ann Rheum Dis 2005, 64(Suppl 3):36.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 3","key":"64_CR48","first-page":"401","volume":"64","author":"D Guh","year":"2005","unstructured":"Guh D, Bansback N, Nosyk B, et al.: Improvement in health utility in patients with psoriatic arthritis treated with adalimumab (Humira). Ann Rheum Dis 2005, 64(Suppl 3):401.","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"64_CR49","first-page":"S509","volume":"50","author":"N Bansback","year":"2004","unstructured":"Bansback N, Barkham N, Ara R, et al.: The economic implications of TNF-inhibitors in the treatment of psoriatic arthritis. Arthritis Rheum 2004, 50(Suppl 9):S509.","journal-title":"Arthritis Rheum"},{"key":"64_CR50","first-page":"1098","volume":"31","author":"KE Hansen","year":"2004","unstructured":"Hansen KE, Hildebrand JP, Genovese MC, et al.: The efficacy of switching from etanercept to infliximab in patients with rheumatoid arthritis. J Rheumatol 2004, 31:1098\u20131102.","journal-title":"J Rheumatol"},{"key":"64_CR51","first-page":"2356","volume":"31","author":"B Haraoui","year":"2004","unstructured":"Haraoui B, Keystone EC, Thorne JC, et al.: Clinical outcomes of patients with rheumatoid arthritis after switching from infliximab to etanercept. J Rheumatol 2004, 31:2356\u20132359.","journal-title":"J Rheumatol"},{"issue":"Suppl 9","key":"64_CR52","first-page":"S187","volume":"50","author":"S Bombardieri","year":"2004","unstructured":"Bombardieri S, Tzioufas AG, McKenna F, et al.: Efficacy evaluation of adalimumab (Humira) in patients with single and multiple prior biologics in the ReAct trial. Arthritis Rheum 2004, 50(Suppl 9):S187.","journal-title":"Arthritis Rheum"},{"key":"64_CR53","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1002\/art.10543","volume":"46","author":"MC Kraan","year":"2002","unstructured":"Kraan MC, van Kuijk AW, Dinant HJ, et al.: Alefacept treatment in psoriatic arthritis: reduction of the effector T cell population in peripheral blood and synovial tissue is associated with improvement of clinical signs of arthritis. Arthritis Rheum 2002, 46:2776\u20132784.","journal-title":"Arthritis Rheum"},{"key":"64_CR54","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1067\/mjd.2002.127247","volume":"47","author":"GG Krueger","year":"2002","unstructured":"Krueger GG, Pap KA, Sough DB, et al.: A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. J Am Acad Dermatol 2002, 47:821\u2013833.","journal-title":"J Am Acad Dermatol"},{"key":"64_CR55","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1002\/art.21870","volume":"54","author":"PJ Mease","year":"2006","unstructured":"Mease PJ, Gladman DD, Keystone EC: Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebocontrolled study. Arthritis Rheum 2006, 54:1638\u20131645.","journal-title":"Arthritis Rheum"},{"key":"64_CR56","doi-asserted-by":"crossref","first-page":"2004","DOI":"10.1056\/NEJMoa030002","volume":"349","author":"M Lebwohl","year":"2003","unstructured":"Lebwohl M, Tyring SK, Hamilton TK, et al.: A novel targeted T-cell modulator, efalizumab, for plaque psoriasis. N Engl J Med 2003, 349:2004\u20132013.","journal-title":"N Engl J Med"},{"key":"64_CR57","doi-asserted-by":"crossref","unstructured":"Papp K, Mease P, Garovoy M, et al.: Efalizumab in patients with psoriatic arthritis: results of a phase II randomized double-blind placebo controlled study. Presented at the International Psoriasis Symposium 2004. Toronto, Ontario; June 10\/2-14, 2004.","DOI":"10.1016\/j.jaad.2003.10.550"},{"key":"64_CR58","doi-asserted-by":"crossref","first-page":"1907","DOI":"10.1056\/NEJMoa035075","volume":"349","author":"JM Kremer","year":"2003","unstructured":"Kremer JM, Westhovens R, Leon M, et al.: Treatment of rheumatoid arthritis by selective inhibition of T-cell activation with fusion protein CTLA4Ig. N Engl J Med 2003, 349:1907\u20131915.","journal-title":"N Engl J Med"},{"key":"64_CR59","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1172\/JCI5857","volume":"103","author":"JR Abrams","year":"1999","unstructured":"Abrams JR, Lebwohl M, Guzzo C: CTLA4Ig-mediated blockade of T cell co-stimulation in patients with psoriasis vulgaris. J Clin Invest 1999, 103:1243\u20131252.","journal-title":"J Clin Invest"},{"key":"64_CR60","doi-asserted-by":"crossref","first-page":"392","DOI":"10.1016\/j.coph.2004.04.003","volume":"4","author":"IB McInnes","year":"2004","unstructured":"McInnes IB, Gracie JA: Interleukin-15: a new cytokine target for the treatment of inflammatory diseases. Curr Opin Pharmacol 2004, 4:392\u2013397.","journal-title":"Curr Opin Pharmacol"},{"issue":"Suppl 2","key":"64_CR61","first-page":"216","volume":"65","author":"A Gibbs","year":"2006","unstructured":"Gibbs A, Gogarty M, Veale D, et al.: Efficacy of anakinra (Kineret) in psoriatic arthritis, a clinical and immunohistological study. Ann Rheum Dis 2006, 65(Suppl 2):216\u2013217.","journal-title":"Ann Rheum Dis"},{"key":"64_CR62","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1517\/14712598.5.5.683","volume":"5","author":"M Mihara","year":"2005","unstructured":"Mihara M, Nishimoto N, Ohsugi Y: The therapy of autoimmune diseases by anti-interleukin-6 receptor antibody. Expert Opin Biol Ther 2005, 5:683\u2013690.","journal-title":"Expert Opin Biol Ther"},{"key":"64_CR63","doi-asserted-by":"crossref","first-page":"AB1","DOI":"10.1016\/j.jaad.2005.10.054","volume":"54","author":"C Krueger","year":"2006","unstructured":"Krueger C, Langley R, Leonardi C, Lebwohl M: Results of a phase II study of CNTO 1275 in the treatment of psoriasis. J Am Acad Dermatol 2006, 54:AB1. Accessible online at http:\/\/www.aad.org\/aad\/memberlogin.htm?return url=%2faad%2fPublicationsResources%2fjaad.htm.","journal-title":"J Am Acad Dermatol"}],"container-title":["Current Rheumatology Reports"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-006-0064-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s11926-006-0064-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s11926-006-0064-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,16]],"date-time":"2025-01-16T21:41:22Z","timestamp":1737063682000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s11926-006-0064-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,9]]},"references-count":63,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2006,9]]}},"alternative-id":["64"],"URL":"https:\/\/doi.org\/10.1007\/s11926-006-0064-9","relation":{},"ISSN":["1523-3774","1534-6307"],"issn-type":[{"value":"1523-3774","type":"print"},{"value":"1534-6307","type":"electronic"}],"subject":[],"published":{"date-parts":[[2006,9]]}}}